The Praluent Market Industry Outlook Improves as Global Demand Continues to Grow

The Business Research Company’s The Praluent Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, November 9, 2026 /EINPresswire.com/ — The Praluent market is undergoing notable changes as new medical strategies and increasing health concerns reshape its landscape. With a strong focus on cardiovascular health and personalized treatments, this market is set to evolve significantly over the next few years. This overview offers insight into the market’s growth projections, key drivers, emerging trends, and regional dynamics shaping its future.

Projected Growth Rate and Market Size of Praluent Through 2026
Historically, the Praluent market’s expansion has been driven by several factors, including a rising incidence of hypercholesterolemia, limitations of statin-only treatments, more comprehensive cardiovascular risk screening, the growing availability of biologic cardiovascular drugs, and greater access to specialist cardiology care. Looking ahead, the market’s growth is expected to continue fueled by an increased emphasis on aggressive lipid-lowering methods, wider adoption of Praluent in secondary prevention, the development of value-based cardiovascular care models, expanding payer support for PCSK9 inhibitors, and heightened awareness around reducing cardiovascular risk. Key trends anticipated during the forecast period include broader use of PCSK9 inhibitors in lipid management, increased utilization in high-risk cardiovascular patients, integration with statin combination therapies, expansion of preventive cardiology programs, and stronger focus on long-term LDL cholesterol management.

Download a free sample of the praluent market report:
https://thebusinessresearchcompany.com/sample_request?id=72717625&type=smp&name=Praluent%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Understanding Praluent’s Role in Cardiovascular Treatment
Praluent is a monoclonal antibody designed to lower high cholesterol levels, specifically targeting low-density lipoprotein (LDL) cholesterol, often referred to as bad cholesterol. It is prescribed for adults with primary hypercholesterolemia or mixed dyslipidemia and is also used to reduce cardiovascular risk in patients with existing heart conditions. Its targeted action helps improve cardiovascular outcomes by managing lipid levels more effectively.

Obesity as a Major Catalyst for Praluent Market Growth
The rising prevalence of obesity is a significant factor expected to propel the Praluent market in the coming years. Obesity, defined as excessive accumulation of body fat with a Body Mass Index (BMI) of 30 or greater, is linked to numerous health risks. The global increase in obesity is largely due to changes in food consumption patterns, including higher intake of ultra-processed foods, sedentary lifestyles, and economic factors favoring unhealthy dietary choices. Praluent addresses obesity-related dyslipidemia by lowering LDL cholesterol through inhibition of PCSK9, enhancing the liver’s ability to clear bad cholesterol from the bloodstream, which supports cardiovascular health and reduces obesity-associated complications. For example, a May 2024 report from the UK’s Office for Health Improvement and Disparities estimated that during 2022–2023, 64.0% of adults in England were overweight or obese, with 26.2% classified as obese. This growing obesity trend is expected to drive demand for Praluent therapies.

View the full praluent market report:
https://thebusinessresearchcompany.com/report/praluent-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Personalized Medicine Adoption Boosting Praluent Demand
Another important driver for the Praluent market is the increasing use of personalized medicine, which tailors treatment based on individual biological characteristics for improved outcomes. Clinicians are progressively favoring therapies aligned with patients’ genetic and biomarker profiles to enhance precision in managing health conditions. Praluent fits well into this approach because its PCSK9-inhibiting mechanism allows for customized LDL cholesterol control based on a patient’s specific cardiovascular risk. For instance, in February 2025, BioSpace, Inc. reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022, highlighting the growing trend toward individualized therapies. This growing adoption of personalized medicine is expected to further accelerate the Praluent market growth.

Regional Overview Highlighting Market Leaders and Growth Areas
In 2025, North America held the largest share of the global Praluent market, reflecting the region’s advanced healthcare infrastructure and widespread adoption of innovative cardiovascular treatments. Meanwhile, the Asia-Pacific region is projected to be the fastest-growing market during the forecast period, driven by expanding healthcare access, rising cardiovascular disease prevalence, and increasing awareness of novel lipid-lowering therapies. The Praluent market report covers key regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa to provide a comprehensive global perspective.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company – www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Media gallery